YOKNEAM ILLIT, Israel, April 4, 2014 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today that the Syneron Candela's leading products will be featured in presentations at LASER 2014, the 34th Annual Scientific Conference of the American Society for Laser Medicine and Surgery (ASLMS), April 2-6 in Phoenix, AZ. This includes an abstract presentation on body contouring with VelaShape III, which received the prestigious Dr. Richard E. Fitzpatrick Clinical Research and Innovations Award. The award was presented to study author Lori A. Brightman, M.D., Associate Adjunct Surgeon, Department of Plastic Surgery, New York Eye and Ear Infirmary.
The Company's broad portfolio, including VelaShape III™, elos Plus™, eTwo™, CO2RE™, ePrime™ and Alex TriVantage™, will be featured in multiple oral abstract presentations, poster exhibits and several presentations in the "New Technology" sessions from leading members of ASLMS, including:
- Roy G. Geronemus, M.D., Director of the Laser & Skin Surgery Center of New York; Clinical Professor of Dermatology, New York University Medical Center; and past President of ASLMS
- Lori A. Brightman, M.D., Associate Adjunct Surgeon, Department of Plastic Surgery, New York Eye and Ear Infirmary
- David J. Goldberg, M.D., Clinical Professor Dermatology, Mount Sinai Hospital
- Sharyn A. Laughlin, M.D., Assistant Professor, Division of Dermatology, University of Ottawa, and Attending Staff at Ottawa Hospital
- Robert A. Weiss, M.D., Associate Professor of Dermatology, Johns Hopkins University; member of the Board of Directors of ASLMS
- Mark B. Taylor, M.D., Gateway Aesthetic Institute & Laser Center
- Eric F. Bernstein, M.D., Clinical Associate Professor of Dermatology, University of Pennsylvania; and Medical Director of Main Line Center for Laser Surgery
Amit Meridor, Syneron's Chief Executive Officer said: "A number of the key products in the Syneron Candela portfolio are being highlighted this year at the ASLMS annual conference. We are pleased that many thought-leaders in laser medicine and surgery utilize our products to help advance the treatment paradigm for patients. We'd like to congratulate Dr. Brightman and her co-authors on receiving the Dr. Richard E. Fitzpatrick Clinical Research and Innovations Award for their study on body contouring using VelaShape III."
Syneron will feature the Syneron Candela product portfolio in its booth #301 at ASLMS Annual Conference.
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.
SOURCE Syneron Medical Ltd.